Eli Lilly and Company (NYSE:LLY) Shares Sold by J.Safra Asset Management Corp

J.Safra Asset Management Corp decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 11.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 601 shares of the company’s stock after selling 80 shares during the quarter. Eli Lilly and Company comprises about 0.0% of J.Safra Asset Management Corp’s portfolio, making the stock its 26th biggest holding. J.Safra Asset Management Corp’s holdings in Eli Lilly and Company were worth $350,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Lipe & Dalton purchased a new stake in Eli Lilly and Company in the 4th quarter valued at $26,000. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at about $27,000. Legacy Financial Group LLC purchased a new position in Eli Lilly and Company in the third quarter worth approximately $35,000. Optiver Holding B.V. acquired a new stake in shares of Eli Lilly and Company during the third quarter valued at about $36,000. Finally, Family CFO Inc acquired a new position in shares of Eli Lilly and Company in the 3rd quarter worth approximately $40,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now directly owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of several research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a report on Monday, April 15th. Truist Financial reaffirmed a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. The Goldman Sachs Group raised their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Finally, Barclays raised their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $7.33 on Thursday, hitting $724.87. The company’s stock had a trading volume of 2,597,583 shares, compared to its average volume of 3,034,002. The stock has a 50 day moving average of $762.75 and a 200-day moving average of $664.94. The company has a market capitalization of $688.74 billion, a price-to-earnings ratio of 124.98, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $370.68 and a 12-month high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.09 EPS. As a group, research analysts predict that Eli Lilly and Company will post 12.52 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.